North America Liver Disease Treatment Market 2026 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

The North America liver disease treatment market reached US$ 7.9 billion in 2023 and is expected to reach US$ 12.28 billion by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/north-america-liver-disease-treatment-market?sb

Key Development:

North America: Recent Industry Developments

✅ In February 2026, Mirum Pharmaceuticals completed the acquisition of Bluejay Therapeutics, gaining worldwide rights to brelovitug, a late-stage antibody therapy targeting chronic hepatitis delta virus (HDV). The deal strengthens Mirum's rare liver disease portfolio and pipeline depth. The therapy holds Breakthrough Therapy designation with Phase 3 data anticipated later in 2026.

✅ In February 2026, Mirum Pharmaceuticals received Health Canada authorization for the tablet formulation of LIVMARLI® (maralixibat) for treating cholestatic pruritus in patients with Alagille syndrome and PFIC. The approval expands dosing flexibility beyond the oral solution. This development enhances treatment convenience and patient adherence in rare pediatric liver diseases.

✅ In February 2026, Bristol Myers Squibb Canada announced public reimbursement of OPDIVO® (nivolumab) plus YERVOY® (ipilimumab) in Ontario for first-line treatment of adults with unresectable or advanced hepatocellular carcinoma. The decision improves patient access to combination immunotherapy. It marks a significant advancement in liver cancer treatment availability within the region.

✅ In December 2025, Gilead Sciences reported sustained efficacy and safety data for LIVDELZI® (seladelpar) in primary biliary cholangitis (PBC), highlighting continued reductions in alkaline phosphatase levels alongside improvements in pruritus. The findings reinforce long-term therapeutic benefits. This supports broader confidence in novel cholestatic liver disease management strategies.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=north-america-liver-disease-treatment-market

Canada: Recent Industry Developments

✅ In February 2026, Health Canada authorized the tablet formulation of LIVMARLI® (maralixibat), broadening treatment options for cholestatic pruritus associated with rare liver diseases. The approval provides additional flexibility for clinicians and patients. It supports improved treatment personalization strategies.

✅ In February 2026, Ontario's FAST Program listed OPDIVO® plus YERVOY® for first-line treatment of advanced liver cancer. The reimbursement strengthens provincial support for innovative immunotherapy approaches. This decision enhances access to next-generation oncology treatments.

✅ In early 2026, Mirum Pharmaceuticals continued advancing volixibat, its bile acid transporter inhibitor designed for cholestatic liver diseases. The therapy targets key mechanisms associated with liver disease progression. Clinical progress signals potential expansion of future treatment options.

✅ In late 2025, pipeline momentum across North America highlighted progress toward multiple liver disease clinical readouts scheduled for 2026. Emerging therapies are focusing on cholestatic conditions and rare liver disorders. These developments underscore continued innovation in liver disease therapeutics.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/north-america-liver-disease-treatment-market?sb

Key Players:

=> Pfizer Inc., AbbVie Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche, Takeda Pharmaceutical Company Limited Ltd, Novo Nordisk A/S, Eli Lilly and Company, Bristol-Myers Squibb Company, Amgen Inc., Gilead Sciences Inc. among others.

Key Segments:

By Treatment Type

Antiviral Drugs dominate the market with 34% share, driven by the high global prevalence of viral liver diseases, particularly hepatitis infections, and continuous advancements in antiviral therapies. Immunosuppressants account for 16%, supported by their critical role in managing autoimmune liver disorders and post-transplant care. Vaccines represent 14%, fueled by expanding immunization programs and preventive healthcare initiatives.

Immunoglobulins capture 9%, reflecting their growing use in immune-related liver conditions. Corticosteroids hold 11%, widely prescribed for inflammatory and autoimmune liver diseases. Targeted Therapy accounts for 10%, driven by precision medicine approaches in liver cancer treatment. Chemotherapy Drugs represent 6%, primarily used in advanced-stage hepatic malignancies.

By Disease Type

Hepatitis leads the market with 31% share, driven by the large patient pool, rising screening initiatives, and increasing treatment accessibility. Non-Alcoholic Fatty Liver Disease (NAFLD) accounts for 22%, reflecting the growing global burden linked to obesity, metabolic syndrome, and sedentary lifestyles.

Autoimmune Diseases represent 14%, supported by improved diagnostic capabilities and rising disease awareness. Liver Cancer holds 18%, driven by increasing incidence rates and expanding adoption of targeted therapies. Genetic Disorders account for 7%, while Other liver conditions capture 8%.

By End User

Hospitals dominate the market with 61% share, driven by complex treatment procedures, advanced diagnostic capabilities, and high patient volumes. Specialty Clinics account for 24%, supported by increasing preference for specialized liver disease management and outpatient care models.

Ambulatory Surgery Centers (ASCs) represent 9%, reflecting the growing shift toward minimally invasive procedures. Others capture 6%.

Outlook & Opportunity Analysis (2024-2031)

The liver disease treatment market is expected to witness steady growth, driven by rising liver disease prevalence, increasing adoption of targeted therapies, expanding vaccination programs, and advancements in precision medicine. Key opportunities lie in early disease detection, biologic therapies, combination treatment approaches, and emerging market expansion, particularly as healthcare infrastructure continues to improve globally.

FAQ

What is the current size of the North America liver disease treatment Market?

A: In 2023, the North America liver disease treatment Market was valued at US$ 7.9 billion, reflecting its strong industry presence.

Q2: How large is the North America liver disease treatment Market expected to be by 2031?

A: By 2031, industry forecasts suggest the North America liver disease treatment Market will grow to around US$ 12.28 billion, demonstrating significant expansion.

Q3: What is the growth rate of the North America liver disease treatment Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 5.8% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.